AR072039A1 - Anticuerpos contra el virus de la hepatitis c - Google Patents
Anticuerpos contra el virus de la hepatitis cInfo
- Publication number
- AR072039A1 AR072039A1 ARP080105506A ARP080105506A AR072039A1 AR 072039 A1 AR072039 A1 AR 072039A1 AR P080105506 A ARP080105506 A AR P080105506A AR P080105506 A ARP080105506 A AR P080105506A AR 072039 A1 AR072039 A1 AR 072039A1
- Authority
- AR
- Argentina
- Prior art keywords
- seq
- humanized antibody
- antigen binding
- binding fragment
- hepatitis
- Prior art date
Links
Classifications
-
- C07K16/118—
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
- C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
- C07K16/1081—Togaviridae, e.g. flavivirus, rubella virus, hog cholera virus
- C07K16/109—Hepatitis C virus; Hepatitis G virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
- G01N33/56983—Viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/005—Assays involving biological materials from specific organisms or of a specific nature from viruses
- G01N2333/08—RNA viruses
- G01N2333/18—Togaviridae; Flaviviridae
- G01N2333/183—Flaviviridae, e.g. pestivirus, mucosal disease virus, bovine viral diarrhoea virus, classical swine fever virus (hog cholera virus) or border disease virus
- G01N2333/186—Hepatitis C; Hepatitis NANB
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/576—Immunoassay; Biospecific binding assay; Materials therefor for hepatitis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Virology (AREA)
- Molecular Biology (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biomedical Technology (AREA)
- Genetics & Genomics (AREA)
- Immunology (AREA)
- Communicable Diseases (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Oncology (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Biochemistry (AREA)
- Wood Science & Technology (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- General Engineering & Computer Science (AREA)
- Physics & Mathematics (AREA)
- Zoology (AREA)
- Biophysics (AREA)
- General Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Gastroenterology & Hepatology (AREA)
- Analytical Chemistry (AREA)
- Food Science & Technology (AREA)
- Pathology (AREA)
Abstract
Un cido nucleico que codifica el anticuerpo humanizado, un vector, una celula recombinante. Reivindicacion 1: Un anticuerpo humanizado que se une a la prote¡na E2 del virus de la hepatitis C o un fragmento de union al ant¡geno del mismo, en donde el anticuerpo humanizado o un fragmento de union al ant¡geno del mismo comprende un dominio variable de la cadena pesada seleccionado del grupo que consiste de las SEQ ID Nø:10, SEQ ID Nø:11, SEQ ID Nø:12, SEQ ID Nø:13, SEQ ID Nø:14, SEQ ID Nø:15, SEQ ID Nø:16, SEQ ID Nø:17 y la SEQ ID Nø:18. Reivindicacion 13: Un metodo para producir un anticuerpo humanizado, o un fragmento de union al ant¡geno del mismo, que comprende cultivar una celula recombinante que contiene al cido nucleico de la reivindicacion 5 de modo tal que el dominio variable de la cadena pesada y/o dominio variable de la cadena liviana codificado es expresado por la celula; y recuperar el anticuerpo humanizado expresado o un fragmento de union al ant¡geno del mismo. Reivindicacion 15: Una composicion farmaceutica que comprende al anticuerpo humanizado o fragmento de union al ant¡geno del mismo de la reivindicacion 3 y un veh¡culo o excipiente aceptable para uso farmaceutico. Reivindicacion 17: Un metodo para tratar o prevenir una infeccion por el virus de la hepatitis C en un ser humano, que comprende administrar una cantidad eficaz del anticuerpo humanizado, o un fragmento de union al ant¡geno del mismo, de la reivindicacion 3. Reivindicacion 25: Un metodo para determinar la presencia o ausencia del virus de la hepatitis C en una muestra, que comprende el uso de un anticuerpo humanizado, o un fragmento de union al ant¡geno del mismo, de la reivindicacion 3.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US606607P | 2007-12-17 | 2007-12-17 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR072039A1 true AR072039A1 (es) | 2010-08-04 |
Family
ID=40801628
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP080105506A AR072039A1 (es) | 2007-12-17 | 2008-12-18 | Anticuerpos contra el virus de la hepatitis c |
Country Status (18)
| Country | Link |
|---|---|
| US (1) | US9193781B2 (es) |
| EP (1) | EP2231704B1 (es) |
| JP (1) | JP5763344B2 (es) |
| KR (1) | KR20100102163A (es) |
| CN (1) | CN101939334B (es) |
| AR (1) | AR072039A1 (es) |
| AU (1) | AU2008341542B2 (es) |
| BR (1) | BRPI0821252A2 (es) |
| CA (1) | CA2708740C (es) |
| CL (1) | CL2008003784A1 (es) |
| IL (1) | IL205795A0 (es) |
| MX (1) | MX2010006767A (es) |
| NZ (1) | NZ585622A (es) |
| PE (1) | PE20091109A1 (es) |
| RU (1) | RU2462475C2 (es) |
| TW (1) | TW200940090A (es) |
| WO (1) | WO2009081285A2 (es) |
| ZA (1) | ZA201003509B (es) |
Families Citing this family (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US12010987B2 (en) | 2004-10-07 | 2024-06-18 | Transmedics, Inc. | Systems and methods for ex-vivo organ care and for using lactate as an indication of donor organ status |
| NZ746484A (en) | 2004-10-07 | 2020-04-24 | Transmedics Inc | Systems and methods for ex-vivo organ care |
| US9078428B2 (en) | 2005-06-28 | 2015-07-14 | Transmedics, Inc. | Systems, methods, compositions and solutions for perfusing an organ |
| US9457179B2 (en) | 2007-03-20 | 2016-10-04 | Transmedics, Inc. | Systems for monitoring and applying electrical currents in an organ perfusion system |
| US9814230B2 (en) | 2008-01-31 | 2017-11-14 | Transmedics, Inc. | Systems and methods for ex vivo lung care |
| MX2011006516A (es) * | 2008-12-17 | 2011-08-04 | Genentech Inc | Terapia de combinacion de virus de hepatitis c. |
| AU2012242578B2 (en) | 2011-04-14 | 2016-07-21 | Transmedics, Inc. | Organ care solution for ex-vivo machine perfusion of donor lungs |
| WO2012151263A2 (en) * | 2011-05-02 | 2012-11-08 | The Johns Hopkins University | A synthetic hepatitis c genome and methods of making and use |
| US20130084301A1 (en) * | 2011-08-30 | 2013-04-04 | Steven Foung | Cluster of Neutralizing Antibodies to Hepatitis C Virus |
| CN103988039A (zh) * | 2011-12-09 | 2014-08-13 | 应用材料公司 | 用于冷却加热管的热交换器和所述冷却的方法 |
| ITFI20120122A1 (it) * | 2012-06-15 | 2013-12-16 | Kedrion S P A 50 | Anticorpi monoclonali capaci di legare la proteina virale e2 loro preparazione ed uso. |
| CN102928595A (zh) * | 2012-10-12 | 2013-02-13 | 武汉康苑生物医药科技有限公司 | 丙型肝炎病毒抗原抗体时间分辨免疫荧光分析法联合检测及检测试剂盒 |
| WO2014116749A1 (en) | 2013-01-23 | 2014-07-31 | Genentech, Inc. | Anti-hcv antibodies and methods of using thereof |
| WO2015042373A1 (en) | 2013-09-19 | 2015-03-26 | Novavax, Inc. | Immunogenic middle east respiratory syndrome coronavirus (mers-cov) compositions and methods |
| RU2539770C1 (ru) * | 2013-12-27 | 2015-01-27 | Татьяна Николаевна Власик | Способ нейтрализации вируса гепатита с, полностью человеческое моноклональное антитело против вируса гепатита с (варианты), композиция полностью человеческих моноклональных антител против вируса гепатита с и гибридная мышь/человек клеточная линия - продуцент полностью человеческих моноклональных антител против вируса гепатита с (варианты) |
| CA2950759C (en) | 2014-06-02 | 2023-02-21 | Transmedics, Inc. | Ex vivo organ care system |
| GB201415714D0 (en) * | 2014-09-05 | 2014-10-22 | Medical Res Council | Antibodies and antigen binding fragments thereof |
| BR112017010520B1 (pt) | 2014-12-12 | 2022-08-30 | Tevosol, Inc | Aparelho e método para perfusão de órgãos |
| IL316791A (en) | 2015-09-09 | 2025-01-01 | Transmedics Inc | Endotracheal tube for an extracorporeal organ therapy system |
| CN105177017B (zh) * | 2015-10-30 | 2020-06-02 | 中国人民解放军第三军医大学第一附属医院 | 抗多亚基因型hcv抗体基因r4-85及其应用 |
| CN105219780B (zh) * | 2015-10-30 | 2020-06-02 | 中国人民解放军第三军医大学第一附属医院 | 抗多亚基因型hcv抗体基因r3-19及其应用 |
| KR102640157B1 (ko) * | 2016-03-22 | 2024-02-27 | 인쎄름 (엥스띠뛰 나씨오날 드 라 쌍떼 에 드 라 흐쉐르슈 메디깔) | 인간화 항-클라우딘-1 항체 및 이의 용도 |
| BR112018074537B1 (pt) | 2016-05-30 | 2023-04-11 | Tevosol, Inc | Método de ventilar um pulmão extraído |
| EP4219556A3 (en) | 2016-12-21 | 2023-10-11 | The United States of America as represented by The Secretary Department of Health and Human Services | Human monoclonal antibodies specific for flt3 and uses thereof |
| US10953089B1 (en) | 2020-01-27 | 2021-03-23 | Novavax, Inc. | Coronavirus vaccine formulations |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR9206131A (pt) * | 1991-06-10 | 1995-05-02 | Lucky Ltd | Hepatite C: diagnóstico e vacinas |
| ITPN960013A1 (it) * | 1996-02-26 | 1997-08-26 | Marcello Piazza | Farmaco atto a proteggere l'individuo dal contagio di epatite virale, ecc. |
| US20060188511A1 (en) * | 1998-11-05 | 2006-08-24 | Foung Steven K | Prevention and treatment of HCV infection employing antibodies directed against conformational and linear epitopes |
| AU2002243259B2 (en) * | 2000-12-01 | 2008-02-07 | The Government Of The United States Of America, As Represented By The Secretary Department Of Health And Human Services | Monoclonal antibodies specific for the E2 glycoprotein of hepatitis C virus and their use in the diagnosis, treatment, and prevention of hepatitis C |
| ITRM20020049A1 (it) * | 2002-01-30 | 2003-07-30 | Biostrands S R L | Frammenti fab di anticorpi monoclonali umani diretti contro la glicoproteina e2 di hcv e dotati di potere neutralizzante in vitro. |
| JP2008532559A (ja) * | 2005-03-19 | 2008-08-21 | メディカル リサーチ カウンシル | ウイルス感染の治療及び予防又は治療及び予防の改善 |
-
2008
- 2008-12-17 CN CN200880125928.5A patent/CN101939334B/zh not_active Expired - Fee Related
- 2008-12-17 NZ NZ585622A patent/NZ585622A/xx not_active IP Right Cessation
- 2008-12-17 JP JP2010538953A patent/JP5763344B2/ja not_active Expired - Fee Related
- 2008-12-17 EP EP08865543.6A patent/EP2231704B1/en not_active Not-in-force
- 2008-12-17 WO PCT/IB2008/003952 patent/WO2009081285A2/en not_active Ceased
- 2008-12-17 RU RU2010129429/10A patent/RU2462475C2/ru not_active IP Right Cessation
- 2008-12-17 CA CA2708740A patent/CA2708740C/en not_active Expired - Fee Related
- 2008-12-17 AU AU2008341542A patent/AU2008341542B2/en not_active Ceased
- 2008-12-17 MX MX2010006767A patent/MX2010006767A/es not_active Application Discontinuation
- 2008-12-17 CL CL2008003784A patent/CL2008003784A1/es unknown
- 2008-12-17 PE PE2008002086A patent/PE20091109A1/es not_active Application Discontinuation
- 2008-12-17 KR KR1020107015856A patent/KR20100102163A/ko not_active Ceased
- 2008-12-17 US US12/809,050 patent/US9193781B2/en not_active Expired - Fee Related
- 2008-12-17 BR BRPI0821252-0A patent/BRPI0821252A2/pt not_active IP Right Cessation
- 2008-12-17 TW TW097149206A patent/TW200940090A/zh unknown
- 2008-12-18 AR ARP080105506A patent/AR072039A1/es not_active Application Discontinuation
-
2010
- 2010-05-16 IL IL205795A patent/IL205795A0/en unknown
- 2010-05-18 ZA ZA2010/03509A patent/ZA201003509B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| TW200940090A (en) | 2009-10-01 |
| HK1144440A1 (en) | 2011-02-18 |
| CL2008003784A1 (es) | 2009-08-14 |
| MX2010006767A (es) | 2010-10-05 |
| PE20091109A1 (es) | 2009-08-12 |
| JP5763344B2 (ja) | 2015-08-12 |
| CN101939334B (zh) | 2015-01-14 |
| EP2231704A2 (en) | 2010-09-29 |
| KR20100102163A (ko) | 2010-09-20 |
| US20110002926A1 (en) | 2011-01-06 |
| WO2009081285A3 (en) | 2010-08-26 |
| US9193781B2 (en) | 2015-11-24 |
| CN101939334A (zh) | 2011-01-05 |
| IL205795A0 (en) | 2010-11-30 |
| RU2462475C2 (ru) | 2012-09-27 |
| RU2010129429A (ru) | 2012-01-27 |
| CA2708740C (en) | 2017-07-18 |
| BRPI0821252A2 (pt) | 2015-06-16 |
| CA2708740A1 (en) | 2009-07-02 |
| JP2011505867A (ja) | 2011-03-03 |
| AU2008341542B2 (en) | 2014-12-04 |
| EP2231704B1 (en) | 2015-08-12 |
| WO2009081285A2 (en) | 2009-07-02 |
| ZA201003509B (en) | 2011-12-28 |
| NZ585622A (en) | 2012-10-26 |
| AU2008341542A1 (en) | 2009-07-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR072039A1 (es) | Anticuerpos contra el virus de la hepatitis c | |
| EA200970477A1 (ru) | Человеческие моноклональные антитела к btla и способы применения | |
| AR126242A2 (es) | Tratamiento del cáncer utilizando receptores de antígenos quiméricos | |
| UA99701C2 (ru) | Человеческое моноклональное антитело, которое специфически связывается с лигандом-1 запрограммированной гибели клеток (pd-l1) | |
| AR085624A2 (es) | Anticuerpos de p-caderina | |
| AR068767A1 (es) | Anticuerpos contra esclerostina, composiciones y metodos de uso de estos anticuerpos para tratar un trastorno patologico mediado por esclerostina | |
| PE20141435A1 (es) | Anticuerpos neutralizantes de citomegalovirus humano | |
| WO2007133623A3 (en) | Peptide diagnostic agent for lyme disease | |
| NZ600768A (en) | Human antibodies to human angiopoietin-like protein 4 | |
| AR045056A1 (es) | Anticuerpos anti-ngf humanos neutralizantes como inhibidores selectivos de la via de ngf | |
| AR069062A1 (es) | Anticuerpo anti-hepcidina | |
| NZ578844A (en) | Human cytomegalovirus neutralising antibodies and use thereof | |
| CA2963470A1 (en) | Antibodies that bind ebola glycoprotein and uses thereof | |
| AR072897A1 (es) | Composiciones y metodos para anticuerpos que se dirigen a la proteina de complemento c5 | |
| BR112012007860A2 (pt) | "anticorpos siglec 15 no tratamento de doença relativa a perda óssea" | |
| RU2015150149A (ru) | Составы на основе биспецифических антител к il-4/il-13 | |
| CO6361947A2 (es) | Combinaciones antitumorales que contienen anticuerpos que reconocen especificamente cd38 y ciclofosfamina | |
| JP6957355B2 (ja) | 血清型交差反応性デング熱中和抗体及びその使用 | |
| CN104447986A (zh) | 一种中东呼吸综合征冠状病毒中和抗体及其制备方法 | |
| PE20240086A1 (es) | Anticuerpos anti-cd122 y usos de estos | |
| AR127271A1 (es) | Anticuerpos biespecíficos que se unen específicamente a cd47 y cd20, y usos de los mismos | |
| CN113527473A (zh) | 一种全人源单克隆抗体及其应用 | |
| DE602005027399D1 (de) | Für humane matriptase spezifische bindungsproteine | |
| WO2020186687A1 (zh) | 一种特异性结合四种血清型登革病毒的人源抗体 | |
| AR095499A1 (es) | ANTICUERPOS MONOCLONALES CONTRA ANTITROMBINA b |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA | Abandonment or withdrawal |